Cutis 2022 Jan;109(1):E33-E35
Dr. Pappas is from the Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania. Dr. Liaqat is from Kaiser Permanente Medical Group, Santa Clara, California. Dr. Halpern is from the University of Pennsylvania, Philadelphia.
We report the case of a 39-year-old woman who presented with generalized malaise; lymphadenopathy; arthritis; dactylitis; ecchymosis; acute onycholysis; and a red, nonpruritic, nonscaly, mottled rash on the right breast 24 hours after the first injections of ixekizumab for psoriasis and psoriatic arthritis. Ixekizumab is a humanized IgG4 monoclonal antibody that binds to IL-17A. Adverse events of ixeki-zumab include infection, inflammatory bowel disease, candidiasis and tinea infections, severe injection-site reactions, arthralgia, headache, infections, neutropenia, and thrombocytopenia. Read More